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Abstract: The fusogenic function of HIV-1 gp41 transmembrane Env subunit relies on 
two different kinds of structural elements: i) a collapsible ectodomain structure (the 
hairpin or six-helix bundle) that opens and closes, and ii) two membrane-transferring 
regions (MTRs), the fusion peptide (FP) and the membrane-proximal external region 
(MPER), which ensure coupling of hairpin closure to apposition and fusion of cell and 
viral membranes. The isolation of naturally produced short peptides and neutralizing 
IgG-s, that interact with FP and MPER, respectively, and block viral infection, suggests 
that these conserved regions might represent useful targets for clinical intervention. 
Furthermore, MTR-derived peptides have been shown to be membrane-active. Here, it 
is discussed the potential use of these molecules and how the analysis of their 
membrane activity in vitro could contribute to the development of HIV fusion inhibitors 
and effective immunogens. 
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I. Introduction: membrane-transferring regions within the globular gp41 
ectodomain. 
 
Membrane fusion comprises a multi-step, highly regulated physiological reaction that 
proceeds mechanically coupled to the basic processes of local rupture (exposure of the 
hydrophobic interior) and deformation (bending) of lipid bilayers (reviewed in [1-4]). 
The human immunodeficiency virus type-1 (HIV-1) relies on the fusogenic activity of 
the envelope glycoprotein (Env) to enter and infect its CD4+ host cells [5-7]. The HIV-1 
fusion machinery shares a number of common features with other fusogenic viral 
glycoproteins [8-11]: functional priming at the cell surface through proteolytic 
processing of Env gp160 precursor to render non-covalently bound surface (gp120) and 
transmembrane (gp41) subunits; an oligomeric organization (homotrimers of gp120-
gp41 heterodimers); fusogenic activity localized into ecto- and transmembrane domains 
of the integral gp41 subunit; and the presence of a fusion peptide (FP), a highly 
conserved, hydrophobic domain, which, in the case of HIV-1, is located at the free 
amino terminus of the fusogenic gp41 subunit. 
From a structural point of view, HIV-1 Env belongs to the “Class I” fusion proteins, 
characterized by their transmembrane subunit’s capacity to fold into a highly stable 6-
helix bundle (6-HB)[6, 10, 11]. In this "hairpin-like" trimeric structure three helices 
pack in the reverse direction against hydrophobic grooves outside a triple-stranded 
coiled-coil, so that the ectodomain amino- and carboxy-termini are placed at the same 
end of the molecule (Figure 1). It is generally assumed that amino-terminal FP 
sequences insert into the target cell membrane in the "pre-hairpin" stage created upon 
receptor/co-receptor binding [12-14]. Subsequent production of the 6-HB structure 
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would therefore induce close apposition of the viral and cell membranes anchored 
through the transmembrane domain (TMD) and the FP, respectively. According to this 
view, the N-terminal FP would function as an inert anchor, i.e., a “secondary” TMD 
that, together with the “primary” TMD, would transmit the force generated by 6-HB 
formation into the target membrane.  
However, two main observations point to an active role of gp41 ectodomain sequences 
at modulating the bilayer elastic stress during membrane fusion. In one hand, mutant 
fusion domains have been isolated that are capable of integrating into target bilayers, 
and yet they do not support fusion activity [15, 16] indicating that simple insertion as an 
inert membrane anchor is not enough to unleash FP function. On the other hand, in the 
context of the 6-HB, the C-terminal helices are not directly followed by TMDs (Figure 
1A). In HIV-1 an intervening sequence of approximately 20 amino acids, termed as the 
membrane proximal external region (MPER), separates both gp41 domains [17, 18]. In 
fact, a soluble and structurally irregular MPER linker might keep the 6-HB far from the 
close contacting dehydrated areas required for membrane fusion initiation (as far as 70 
Å apart from the viral membrane). It was thus argued that the transmission of the force 
generated upon folding into the 6-HB required the establishment of direct contacts 
between the MPER and the HIV membrane [19]. 
Wimley-White (WW) hydrophobicity scales can provide valuable tools for the detection 
of membrane-active domains, particularly useful in the case of viral products that insert 
into membranes of the host cells (reviewed in [20, 21]). These scales are based on 
partitioning free energies of individual amino acids (including the peptide bond) from 
water into membrane interfaces (!Gwiu) or octanol (!Gwio) [22]. When applied to HIV-1 
gp41 ectodomain the hydrophobicity-at-interface WW scale displays a positive peak 
that is indeed coincident with the N-terminal FP sequence (Figure 1A). In addition, a 
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positive maximum spanning MPER is detected at the C-terminus, thereby indicating 
that both hairpin ends are endowed with the capacity for transferring from water into the 
membrane interface (MI). The gp41 ectodomain membrane-transferring regions 
(MTRs) can be operationally defined based on two distinct characteristics: i) their 
favorable free energy of partitioning from water into the MI; and ii) their intrinsic 
capacity for perturbing the lipid bilayer architecture upon insertion (membrane activity).  
Thus, MTR refer to sequences, other than the TMD, which bear the potential for 
partitioning from water into the membrane interface [20], and that by doing so may 
compromise the bilayer integrity [18]. However, these sequences do not function as 
membrane anchors recognized by the translocon as stably integrated transmembrane 
helices during glycoprotein synthesis [23]. Explicitly, in the full gp41 sequence, the 
ectodomain FP and MPER sequences [24-26], and the cytoplasmic tail lentivirus lytic 
peptides (LLPs) [24, 27, 28], would fulfill the requirements to qualify as MTRs. 
MTR partitioning into membranes has been quantitatively assessed in vesicular model 
systems using representative synthetic peptides [12, 29-37]. These studies not only 
confirm the predicted high affinity of MTRs for the membrane interface, but also 
support their role as promoters of lipid bilayer destabilization [12, 13, 34, 36-38]. In 
principle MTR-s might promote fusion by reducing the formation energies of the lipidic 
intermediates of fusion, and/or by accelerating the opening of fusion pores [39-41]. 
Given their common membrane topology at equilibrium, i.e., inserted at the level of the 
interface-hydrocarbon region of one monolayer, it has been proposed that MTRs may 
induce lateral stress in the hydrocarbon region of the external monolayer and/or 
selectively induce an increment of its surface [34, 42-45]. These effects would result in 
the creation of bulges (or dimples) that protrude from the membrane plane [46]. The 
tops of these structures are highly curved, an arrangement that can facilitate the 
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formation of lipidic contacts between fusing bilayers [46]. Alternatively, based on the 
evidence that MTRs may lower the membrane rupture tension [47], it has been 
proposed that a plausible mechanism of MTR-mediated fusion-promotion could be the 
destabilization of bilayer diaphragms at hemifusion intermediates [40]. Yet another line 
of evidence derived from diffuse x-ray scattering experiments, indicates that the FP 
inserted in membranes might reduce the bending energy, and, hence, facilitate the 
formation of curved lipidic intermediates of fusion [41]. 
 
 
II: HIV-1 fusion inhibition by targeting the fusion peptide 
 
The most widely accepted mechanism of HIV-1 Env-mediated fusion introduced in the 
previous section encompasses two key processes (Figure 1B): 1) Insertion of MTRs into 
the fusing membranes, and 2) Collapse of the pre-hairpin intermediate into an 
energetically stable 6-HB structure. Since entry inhibition may block early stages of 
viral infection, the large conformational changes that are the energy source for 
membrane fusion constitute an important target in development of antiviral therapies. 
The HIV fusion inhibitors derived from the C-terminal heptad repeat region (CHR) 
comprise a family of peptide-based compounds, some of them, such as the T-20 
derivatives, currently in clinical use [48]. These molecules dominantly compete with 
gp41 helical sequences for binding to hydrophobic grooves transiently exposed at the 
ectodomain surface [5, 6]. Thus, it is postulated that T-20-like peptides block close 
contact between cell target and viral membranes by preventing 6-HB formation. 
Although highly effective, the clinical use of these compounds is circumscribed to 
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rescue therapies against multidrug resistant viruses [48]. Bioavailability issues, 
including rapid proteolytic degradation, and consequent requirement of high doses 
delivered by injection, pose a serious limitation to their wider application. 
In theory the gp41 MTRs that transfer into and perturb membranes may comprise 
alternative/complementary targets for antiviral development. MTR membrane-activity is 
dependent on the adoption of structurally defined oligomeric complexes at membrane 
surfaces, a requirement that might explain, at least in part, their high degree of sequence 
conservation [19, 30-32]. Mutagenesis studies have put forward the absolute 
requirement of the FP sequence for gp41 fusogenic activity [49-51]. Amino acid 
homology between fusion proteins of different viruses is usually of less than 20%. In 
contrast FP homology for the same proteins can be as high as 90% [52]. FPs are also 
unusually enriched in Ala and Gly residues [53]. Comparable high degrees of residue 
conservation and Ala/Gly content are not found in other membrane-associated 
hydrophobic protein domains as signal sequences or transmembrane anchors, 
suggesting that FP sequences have evolved constrained by a selective pressure that 
cannot be explained by simple requirements of hydrophobicity or amphipathicity. 
Supporting the existence of a tight structure-function relationship, Longo et al. [54] 
identified a pore-formation activity of the functional FP well below the membrane 
rupture tensions caused by simple transfer of mass to the bilayers. Thus, the ability to 
perturb the bilayer architecture after insertion seems to be an intrinsic feature of 
functional viral FPs, which probably requires formation of specific membrane-
embedded complexes [42].  
Interference with formation of these structurally defined oligomeric complexes might 
also explain the inhibitory effect displayed by short peptides derived from the FP 
sequence in cell systems. A hexapeptide which was identical in amino acid sequence to 
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the gp41 N-terminus was found by Owens and coworkers [55] to completely inhibit 
syncitium formation mediated by HIV-1 envelope glycoproteins expressed at the 
surface of HeLa CD4+ cells. The inhibitory effect was sequence-specific and dose-
dependent. Longer HIV-1 FPs inhibited HIV-induced syncytium formation and antigen 
production in infected cells [56]. When peptide solubility was increased by a C-
terminus conjugation to charged polymers an increase in inhibitory activity was found; 
in contrast, such modification to the N-terminus abolished inhibition. Kliger and 
coworkers [31] demonstrated inhibition of cell-cell fusion induced by expressed 
gp120/41 using 33-mer sequences representing the gp41 N-terminus. Again a functional 
feature of these sequences was shown to be their capacity to assemble high order 
complexes. In later developments, these authors demonstrated that both, a synthetic all 
D-amino acid peptide (D-amino acid stands for the use of the D-stereoisomers of the 
natural amino acids) corresponding to the same sequence, and a peptide in which the 
highly conserved Ile4, Phe8, Phe11, and Ala14 residues were replaced by their D-
counterparts, were able to bind to the wild-type peptide in the membrane, inhibiting cell 
fusion mediated by the HIV-1 envelope glycoprotein [57, 58]. 
Thus, FP function emerges as an alternative therapeutic target for the development of 
fusion inhibitors. Supporting this view, Münch and co-workers [59] have recently 
reported the isolation of a naturally produced blood plasma oligopeptide, capable of 
blocking HIV-1 infection by targeting gp41 FP. This peptide, termed by these authors as 
VIRIP (virus-inhibitory peptide), was purified from hemofiltrate obtained from patients 
suffering from chronic renal failure. VIRIP was identified as a derivative from the C-
terminal sequence of circulating serine protease inhibitor "1-antitrypsin. This original 
sequence inhibited infection of PBMC by HIV-1 with IC50-s of about 20 µM, in a 
highly sequence-specific manner. Even though several residues proved to be absolutely 
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required for the inhibitory activity, VIRIP could be optimized by adding non-natural 
amino acids at positions that tolerated substitution by Ala, and/or by introducing 
intramolecular cyclic motifs by disulfide bonds. This optimized versions resulted as 
potent as T-20 in blocking viral infection and were devoid of cellular toxicity.  
The FP sequence was identified as the VIRIP’s molecular target as evidenced by its 
capacity for inhibiting synthetic FP-promoted hemolysis [60]. Notably, a positive 
correlation was established between anti-hemolytic activity and infection inhibition 
capacity, i.e., VIRIP derivatives showing improved anti-HIV capacity were also more 
potent interfering with FP-induced hemolysis. Finally, the structure of FP in complex 
with the optimized VIRIP derivative VIR-165, was elucidated in NMR experiments 
(PDB entry: 2JNR). Structural analyses of the complex revealed that these peptides 
bracket together via hydrophobic interactions of the amino acid side chains. 
More recently, Forsmann et al. [61] have reported on the outcome of a 10-day 
monotherapy with the optimized VIR-576 derivative of VIRIP applied to HIV-1-
infected patients. These authors evaluated the safety, pharmacokinetics and antiviral 
efficacy of VIR-576 in 18 patients. Treatment with VIR-576 was well tolerated by 
patients, and reduced their plasma viral load by 1.23 log10 copies. These promising 
results constitute a first proof of concept that VIRIP can suppress viral replication in 
infected individuals, and support the clinical potential of FP inhibitors.  
 
III. Synthetic peptide combinatorial libraries as a potential source of antiFP 
compounds. 
 
Eckert et al. [62] described inhibitory peptides based on D-amino acids that targeted a 
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pocket on the surface of the central trimeric coiled-coil within gp41. These D-amino 
acid-based pocket-specific inhibitors of entry (PIE) have been more recently optimized 
by Welch et al. [63]. As discussed by these authors, D-amino acid-based peptides with 
fusion inhibitory activities have several potential advantages over the natural L-amino 
acid-based peptide inhibitors: i) they are resistant to proteases; ii) they have the 
potential to be administered orally; and iii) they are structurally more diverse, a feature 
allowing easier targeting to geometrically complex surfaces. 
Synthetic combinatorial peptide libraries have been also developed based on D-amino 
acids. In particular, Houghten’s laboratory developed in the nineties the concept of 
positional scanning synthetic combinatorial libraries (PS-SCL; [64, 65]) that was also 
later explored by others [66-68]. In the peptide-based PS-SCL the peptide mixtures used 
to be C-amidated and N-acetylated. The most popular size for these libraries is the 
hexapeptide. Then an hexapeptide-D-amino acid-based library is composed of six 
individual positional SCLs represented by the formulae: Ac-o1xxxxx-NH2, Ac-
xo2xxxx-NH2, Ac-xxo3xxx-NH2, Ac-xxxo4xx-NH2, Ac-xxxxo5x-NH2 and Ac-
xxxxxo6-NH2 (o: defined by one of 20 D-amino acids; x: close to equimolar mixture of 
19 D-amino acids, cysteine omitted). Each peptide mixture is composed of 
approximately 2.5 million (195) individual hexapeptides, for a total of over 50 million 
(20 x 195) hexamers. Each positional SCL addresses a separate single position of the 
sequence, and the PS-SCL approach relies on the connectivity between the amino acids 
defining the most biologically active mixtures at each positions being addressed. It was 
early demonstrated that the screening of a D-amino acid-based PS-SCL was useful for 
the identification of inhibitors of membrane active natural (i.e., L-amino acid) peptides 
such as melittin through peptide-peptide interactions [69, 70]. 
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 Part IV. antiFP isolation from a PS-SCL based on pore-forming membrane 
activity 
 
In search for alternative fusion inhibitors we screened a PS-SCL for the presence of 
anti-MTR compounds. Analysis of the molecular mechanisms underlying MTR activity 
in the whole gp41 protein is not viable as yet. This has warranted the development of in 
vitro assays based on the use of representative synthetic peptides and model membranes 
[21, 34]. The ANTS/DPX leakage assay for pore formation is widely used to assess the 
membrane activity of bioactive peptides in liposomes [71]. In particular, using this 
assay a significant correlation was established between the effects of FP mutations 
blocking gp41 fusogenic activity, and the effects displayed by the same sequence 
alterations on the capacity of synthetic analogs to form lytic pores in vesicles [29, 30, 
32, 33, 42]. The process of FP pore formation in 1-palmitoyl-2-
oleoylphosphatidylglycerol (POPG) vesicles has been successfully modeled by Nir and 
co-workers [29, 72] under the following mechanistic assumptions (Figure 2A):  
1) First a rapid stage of peptide binding to the vesicle membranes takes place (see 
also panel C). 
2) Coupled to partitioning, the FP attains a helical structure at the membrane-
interface. 
3) Following the structuring step, a surface aggregation of helical peptides occurs.   
4) When the structure and conformation of the peptides are appropriate, the 
aggregates that have reached a critical size will form a permeating pore.  
In this model, the kinetics of leakage (panel C) is dictated by the kinetics of surface 
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aggregation, bilayer translocation and aqueous pore opening, since once a pore has 
formed the leakage of all the contents occurs within less than 1s, thus yielding a finite 
final extent. In accordance with this model, FP blocking agents may potentially act by 
interfering with partitioning (i.e., generating a water soluble complex with reduced 
!Gwiu), hindering the conformational changes and/or oligomerization processes taking 
place at the bilayer surface, or occluding the aqueous channel.  
FP-dependent pore formation in POPG vesicles was therefore used as the functional 
assay to screen the PS-SCL for the identification of compounds that inhibited FP 
activity [73]. The peptide mixtures that defined the library, were pre-mixed with FP in 
DMSO prior to addition to the POPG large unilamellar vesicle (LUV) suspension. 
Figure 2B illustrates the effects on FP-induced leakage induced by representative 
mixtures in the Ac-xxo3xxx-NH2 sub-library (defined amino acids at position 3). Each 
sub-library addressed a separate position of the hexapeptide and, when used in concert, 
the data provided information about the most important amino acid residue at each 
position [74]. The so-called “library deconvolution” consisted in selecting the most 
active mixtures as inhibitors, and identifying the relevant amino acid residues for each 
position. The screening data allowed not only the selection of amino acids at each 
position, which should lead to active individual sequences, but also gave information on 
the relative importance of each residue within the active sequences. Our criteria for the 
selection of amino acids for the synthesis of individual sequences derived from the PS-
SCL were significantly higher inhibitory activity as compared to the peptide mixtures 
within the same single positional SCL, and/or difference in chemical character within 
the same single positional SCL and/or throughout the PS-SCL. As a result of this 
focused process the following mixtures were selected: g(1)-p/q/s(2)-i(3)-d(4)-e/q(5)-
v(6). Then 1x3x1x1x2x1=6 D-amino acid hexapeptide sequences were synthesized and 
 12 
assayed against FP. From this initial set, three sequences resulted clearly inhibitory (ie., 
they induced >50 % reduction in observed leakage): Ac-gqidev-NH2, Ac-gqidqv-NH2 
and Ac-gsidqv-NH2. Moreover, among these sequences, Ac-gqidev-NH2 (82-2) and 
Ac-gqidqv-NH2 (82-5) also inhibited syncytium formation induced by gp41 expressed 
at cell surfaces. 
Preliminary data displayed in Figures 2 C,D advance some clues on the mechanism 
underlying FP-induced leakage inhibition by the isolated 82-2 and 82-5 hexapeptides. 
Insertion into the non-polar lipid bilayer milieu of FP fluorescently labeled with NBD 
caused a sudden increase in the fluorescence emission intensity of the probe (dotted line 
in panel C). Inhibitory D-hexapeptides appear to not interfere with water-membrane 
partitioning as judged from their incapacity to preclude this insertion process (not 
shown). The NBD fluorescence increase, which was not blocked by hexapeptide 
addition, was followed by the onset of ANTS/DPX leakage. In contrast to insertion, D-
hexapeptide addition blocked ongoing leakage from vesicles that had incorporated the 
FP, suggesting that the membrane-bound FP population may constitute the actual target 
for the inhibitors.  
As shown in Figure 2E, the 82-2 and 82-5 compounds inhibited fusion in a dose-
dependent manner showing apparent 50% inhibitory concentration (IC50) values of ca. 
20 µM and 100 µM, respectively. The observation that a sequence bearing D-proline in 
position 2 (Ac-gpidqv-NH2) was not inhibitory of FP membrane activity or gp41-
induced cell-cell fusion emphasizes the specificity of the process. The inhibitory 
potency of these compounds was ca. x500-1000 times lower (when weight was 
considered) than that exhibited by the T-20 peptide in the same assay [73], but 
nonetheless comparable to that reported for the first generation of PIEs in similar cell-
cell fusion inhibition assays [62]. Research work is under progress in our laboratories in 
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order to precisely elucidate the stage between bilayer partitioning and pore-opening that 
is targeted by D-hexapeptides. Our expectation is that characterizing the inhibition 
mechanism of pore-formation in the vesicular systems will provide valuable starting 
information to attempt the resolution of the mechanism underlying gp41-induced fusion 
inhibition. We also surmise that isolating the FP stage relevant for inhibition may guide 
future structural studies. Recent structure-assisted redesign of PIE sequences has 
yielded optimized versions displaying IC50 values in the order of pM in neutralization 
assays [63]. Thus, the first generation of anti-FP D-hexapeptides might also comprise 
leading platforms for inhibitor optimization in the near future. 
 
 
 
IV. MPER structure-function  
 
 
The MPER sequence encompasses the second class of gp41 MTR. Based on mean 
interfacial hydrophobicity calculations we proposed this sequence to span 
664DKWASLWNWFNITNWLWYIK683 Env residues [18, 24]. Compelling mutational 
analysis by Salzwedel and co-workers [17] provided evidence to support the 
involvement of this interfacial gp41 stretch in HIV-1 fusion. Deletion of the entire 
sequence (Env residues 665-682) abrogated the ability of the glycoprotein to mediate 
cell-cell fusion without affecting the normal maturation, transport, or CD4-binding 
ability of the protein. The same fusion phenotype was demonstrated for W(1-5)A, an 
MPER mutant devoid of interfacial hydrophobicity by substituting alanine residues for 
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the five tryptophan residues within this sequence [17, 21]. Subsequent functional studies 
revealed that membrane fusion induced by gp41 devoid of MPER interfacial 
hydrophobicity was arrested at the stage of non-expanding small fusion pores [75], 
which suggests a role during post-lipid mixing stages [76]. 
The membrane-activity of MPER-derived peptides detected in vitro provides 
experimental evidence to support a functional role for this gp41 MTR during fusion [18, 
25, 77]. Characterization of the HIV-1 lipidome has revealed high levels of cholesterol 
(Chol) and sphingomyelin (SPM) [78-80], an observation that correlates with the 
selectivity for specific segregated membrane regions through which virions emerge 
during maturation [81, 82]. The membrane activity of the MPER-derived peptide 
664DKWASLWNWFNITNWLWYIK683 (PreTM) was modulated by these envelope 
lipids [77]. Specifically, Chol greatly stimulated PreTM’s lytic activity and activated its 
fusogenic capacity [77]. When PC, SPM and Chol were combined to emulate conditions 
of liquid ordered (Lo)-liquid disordered (Ld) lipid domain segregation, putatively 
existing at the external membrane monolayer of HI virion, high levels of PreTM surface 
self-aggregation, concomitant to an enhancement in fusion and lytic activities were 
observed at low peptide doses (in the order of 1:1000 peptide-to-lipid ratio). Conditions 
described to disturb occurrence of lateral separation of Lo-Ld lipid phases in these 
systems, reproduced the high peptide-dose requirements for leakage as found in pure PC 
vesicles and inhibited fusion [77]. Thus, the lipid dependence observed in the vesicular 
systems suggests a functional role for MPER membrane activity in destabilizing the 
envelope lipid bilayer architecture at the loci of fusion. 
The possible existence of a direct interaction between Chol and PreTM domain was 
already posited by Salzwedel et al.[17]. MPER carboxy-terminal LWYIK sequence has 
been identified as a potential "cholesterol recognition/interaction amino acid consensus" 
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(CRAC) domain functional in fusion [83-87]. Recently reported experimental evidence 
and modeling studies provide the physicochemical grounds for a direct interaction of 
MPER-CRAC with Chol [84, 85, 88, 89]. MPER-Chol interaction would be based on 
two capacities of CRAC sequence, namely, wrapping and blocking of the interfacial 
cholesterol OH group by H-bond interactions, and stacking of aromatic side chains with 
A ring of cholesterol.  
The functional importance of MPER lytic activity for gp41-induced fusion has been 
recently demonstrated by Vishwanathan and Hunter [90]. These authors designed gp41 
chimeras that replaced all or part of MPER with indolicidin-based sequences. 
Indolicidin is a Trp-rich, antimicrobial and hemolytic peptide that forms pores in 
membranes. Thus, indolicidin and MPER have in common the unusual high number of 
tryptophans and their capacity to permeabilize membranes. These authors hypothesized 
that if MPER-induced membrane perturbations were required for gp41 fusogenic 
function, its replacement with indolicidin would produce functional Env glycoprotein. 
Some of the produced gp41 chimeras indeed retained fusion activity [90], therefore 
demonstrating that MPER can be replaced by a membrane-disruptive foreign sequence 
and preserve its biological function. 
Structural studies support that membrane-active MPER may fold within the low-
polarity membrane-interface environment adopting a helical conformation, and also 
self-aggregate therein (Figure 3). NMR spectroscopy studies by Schibli et al. [43] 
revealed the formation of a well-defined helical structure for 
665KWASLWNWFNITNWLWYIK683 peptide monomers in dodecylphosphocholine 
(DPC) micelles (Figure 3A, left panel). Four of the five tryptophan residues, as well as 
the tyrosine residue, formed a “collar” of aromatic residues along the axial length of the 
helix. Nuclear Overhauser effects to the headgroup and interfacial protons of protonated 
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dodecylphosphocholine confirmed that the aromatic residues are positioned within the 
membrane-water interface of a phospholipid bilayer sustaining a "Velcro-like" 
interaction. The bulk of the polar residues are positioned on one face of this structure, 
with the hydrophobic phenylalanine side chain on the opposing face, forming an 
amphipathic structure.  
Subsequent analyses of the MPER sequence including the application of the 
hydrophobic-at-interface moment to the numerous mutations generated by Salzwedel 
and coworkers [17] revealed that this gp41 MTR might be segmented into two 
segregated hydrophobic subdomains [19]. The N-terminal domain was found to span a 
helical amphipathic-at-interface sequence or AIS domain, a structural motif conserved 
among members of the lentivirinae genus [19, 91, 92]. Supporting the functional 
relevance of this particular organization, a number of blocking deletions invariably 
correlated with the ablation and/or merging of interfacial subdomains, while the effect 
of several Trp to Ala mutations on function correlated with the preservation of the 
interfacial hydrophobicity distributed into two subdomains [19, 21]. 
A more recent DPC-NMR structure reported by Sun et al. [93] provided the structural 
basis for the functional segmentation of this gp41 MTR (see also Figure 3A, right 
panel). The MPER sequence 662ELDKWASLWNWFNITNWLWYIK683 analyzed by 
these authors was elongated at the N-terminus by including the E662 and D664 polar 
residues. The conformationally defined elements present in the structure included a 
tilted "-helix (664-672), a short hinge connection (673-674), and a flat helix running in 
parallel to the membrane plane (675-683). The N-terminal segment contained a two-turn 
"-helix, whereas a one-turn "-helix was combined with a short 310-helix within the C-
terminal segment. This kinked structure optimizes the hydrophobic surface for 
membrane insertion with 4 out of the 5 Trp residues plus F673 facing the 
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MI/hydrocarbon core (HC) interface. Moreover, side-chains of most polar residues 
remain solvent exposed. Remarkably, as pointed out by these authors, the membrane-
buried residues are the most conserved, whereas the hydrophilic-exposed residues seem 
to be subject of greater variability. 
Low-resolution structural techniques provide additional evidence for the existence of 
monomeric and multimeric MPER states in a membrane environment [19]. To illustrate 
this point, circular dichroism (CD) spectra of MPER-derived PreTM and AISpreTM 
peptides are compared in Figure 3B. Spectra of monomeric helical peptides in DPC 
micelles display spectra with a characteristic [!]222/[!]208 ratio <1 (dotted traces in panel 
C). By comparison, CD spectra of these peptides incorporated into PC:Chol vesicles at a 
1:33 peptide-to-lipid mole ratio (continuous traces) resulted in an increase of the 
intensity of the 222 nm peak. This effect was more prominent for the PreTM peptide, in 
which case the [!]222/[!]208 ellipticity ratio >1 unambiguously supports the existence of 
helix-helix interactions such as those described for heterodimeric coiled-coils and/or 
transmembrane helical bundles [94-96]. Thus, low-resolution structural data are 
compatible with the existence of a monomeric helical structure, prevalent in membrane-
mimicking detergent micelles, which would self-associate at membrane surfaces. 
Indeed, this homo-oligomerization phenomenon is promoted by Chol and correlates 
with the pore-forming capacity of MPER-derived peptides [19, 21, 77]. 
 
 
V. MPER as a target for fusion inhibition. 
 
The ability displayed by MPER-derived PreTM peptide to self-associate in membranes 
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raised the possibility that formation of structurally defined MPER homo-oligomers 
might take place at some stage during gp41-induced fusion process [19]. It was assumed 
that this process might represent an alternative target for potential inhibitors. 
Competition with MPER self-oligomerization, and hence, fusion inhibition was tested 
using free PreTM peptide in HIV-1 Env-induced cell-cell fusion assays [19]. The 
PreTM peptide inhibited gp41-induced fusion in a dose-dependent manner with an 
apparent IC50 value of 577 nM. A Trp(1-3)Ala mutant-like peptide unable to form 
homo-oligomers was used as negative control and shown to be devoid of the inhibitory 
effect. In control experiments, neither of these two peptides inhibited influenza 
hemaglutinin-mediated fusion implying that PreTM inhibitory effect was through its 
interaction with HIV envelope protein, and not through its partitioning into cell 
membranes and causing lipid-mediated effects. 
The potential of the lentiviral MPER region as a target for fusion inhibitor development 
is better exemplified in the case of the Feline Immunodeficiency Virus (FIV) 
transmembrane glycoprotein. A cognate 20-mer peptide derived from FIV MPER, 
potently inhibited viral infectivity in tissue culture (IC50 " 4 nM) [97-99]. Antiviral 
activity of the leading MPER-derived sequence was found to map to a short segment 
containing three conserved Trp residues. Thus, further analyses focused on a derivative 
of eight amino acids (770WEDWVRWI777), designated C8, which still displayed potent 
antiviral activity (IC50 " 40 nM). C8 activity was found to be dependent on conservation 
of the Trp motif, most likely because these residues are responsible for its 
conformational propensity. Furthermore, the retroinverso analogue of this peptide (riC8) 
has been shown to be effective in vivo, in experiments demonstrating its ability to 
decrease mean viral load when administered to chronically FIV-infected cats [99].  
As mentioned in the previous section, perturbation of the integrity of lipid bilayers by 
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peptide doses relevant for spike density in the viral membrane [100] and the Chol effect 
on this phenomenon [101, 102] point to membrane restructuring during fusion as the 
gp41 MPER functional activity. The evidence that broadly neutralizing antibodies can 
inhibit the membrane-restructuring processes observed in vesicular systems reinforces 
that idea. In particular, the broadly neutralizing anti-gp41 2F5 and 4E10 monoclonal 
antibodies (mAbs), which recognize linear epitopes located within MPER (reviewed in 
[103, 104]), block MPER membrane activity assayed in vesicular model systems [92, 
105-107]. The Fab structures solved in complex with epitope-representing peptides 
revealed the sequences in contact with 2F5 (657EQELLELDKWASLW670) and 4E10 
paratopes (672WFNITNWLW680) [108-110]. Thus, the full 2F5 epitope roughly 
corresponds to the MPER AIS, while the 4E10 epitope starts at the junction between the 
hydrophobic subdomains and ends close to the MPER C-terminus.  
These crystal structures also reveal long third complementarity-determining region of 
the heavy chains (CDR H3s) containing solvent-exposed aromatic residues. 
Accordingly, it has been suggested that 2F5 and 4E10 antibodies share a common 
adaptive trait for epitope recognition at the membrane surface [108, 111, 112]. Recent 
mutagenesis studies actually indicate that neutralizing activity might be dependent on 
antibody-membrane association, which would require the preservation of hydrophobic-
at-interface CDR H3 loop residues [113-116]. Thus, determining the optimal conditions 
for membrane-inserted epitope recognition and subsequent membrane activity blocking 
may provide useful information for the rational design of effective liposome-peptide 
immunogens. 
In principle, antibody recognition-blocking may be conditioned by the structure and 
dynamics of the membrane-embedded MPER sequence, which are in turn predicted to 
depend on the length and composition of the MPER-derived peptide sequence 
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considered (i.e., the inclusion of the different hydrophobic subdomains [117]), and the 
lipid composition of the model membrane (i.e., the presence of envelope lipids Chol 
and/or SPM [105, 106]). Figure 3 compiles results on mAb4E10-MPER peptide 
interactions reported in previous works [92, 105, 106], which exemplify the effect of 
peptide structure on mAb recognition and membrane-activity blocking. The PreTM 
peptide is structurally represented by the interfacial helix described by Schibli et al. 
[43](PDB entry: 1JAV). Within this continuous structure, residues W672 and F673 face 
towards the HC region of the membrane. A comparable orientation of these residues 
was observed within the bipartite structure reported by Sun et al. [93] (PDB entry: 
2PV6). This structure might be representative of longer MPER specimens, such as 
AISpreTM, bearing higher polarity at the N-terminus. Both structures also expose N671 
to the solvent. In contrast, the W680 residue remains buried into the MI-HC interface 
within the shorter, continuous helical 1JAV structure, while the chain reorientation 
introduced by the connecting hinge induces its exposure to solvent within the longer 
2PV6 structure.  
Lorizate et al. [105] reported surface pressure measurements compatible with the partial 
extraction by 4E10 of PreTM peptide from lipid monolayers (see also Figure 4) and Sun 
et al. [93] provided electron-paramagnetic resonance data compatible with 4E10 epitope 
extraction from the longer 662-683 MPER peptide inserted into lipid bilayers. These 
authors observed that extracted W672 and F673 side chains rearrange within the 4E10 
paratope, and that, particularly the latter residue, flips vertically and inserts deeply into 
the epitope-binding pocket. Sun et al. [93] also hypothesized that solvent exposed N671 
and W680 were key residues in 4E10 recognition of membrane-inserted MPER by 
guiding the initial contacts with CDR3 regions of the antibody. Thus, given the fact that 
only the former would be accessible in a membrane-bound state, mAb4E10 is predicted 
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to recognize-block the shorter MPER-derived PreTM peptide with lower affinity.  
The Figures 3C and D display respectively peptide-induced leakage inhibition and 
antibody-vesicle association results, which, in conjunction, provide evidence for higher 
antibody affinity towards the membrane-bound peptide exposing W680 to solvent. 4E10 
blocked the leakage process induced by the long AISpreTM peptide with an IC50 of ca. 
10 nM, while an order of magnitude higher IC50 value of ca. 100 nM was measured for 
the inhibition of leakage induced by the shorter PreTM peptide (Figure 3C). The actual 
levels of mAb-liposome association, as detected by flow-cytometry, also reflected the 
higher affinity of 4E10 towards vesicles containing the longer MPER peptide (Figure 
3D). The implication of W680 in 4E10 recognition at the membrane surface therefore 
supports that this invariant residue should be exposed to the immune system in 
membrane-model formulations aimed at eliciting 4E10-like neutralizing antibodies. 
Previously published results also support the capacity of lipids for modulating the 
membrane-inserted epitope recognition process. Explicitly, blocking by 4E10 antibody 
of membrane-restructuring induced by MPER-derived peptides has been shown to 
depend on the presence of Chol [105, 106], a phenomenon that suggests an adaptation 
of the antibody for recognition of gp41 sequences in the environment provided by the 
virion external membrane-interface. In contrast, 4E10 did not efficiently blocked 
perturbations induced in PC:SPM vesicles, presumably because the MPER epitope gets 
occluded in the transmembrane pores responsible for permeabilization of this type of 
vesicles [105, 106]. 
This point is further illustrated by the results displayed in Figure 4. The depth of 
insertion of peptides bound to membrane-surfaces can be assessed by determining their 
accessibility to proteolytic degradation by proteinase K [118]. Figure 4A displays the 
rhodamine fluorescence dequenching that occurs upon protease treatment of vesicles-
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containing PreTM peptide labeled with this fluorophore. Accessibility to the membrane-
bound peptide increases in the following order PC:SPM<PC:Chol<PC:SPM:Chol. 
Results shown in panels B and C demonstrate that the degree of accessibility correlates 
with the capacity of 4E10 for extracting the peptide from lipid monolayers and for 
binding to large unilamellar vesicles containing the peptide, respectively. These data 
also correlate the presence of Chol with the accessibility for antibody binding. Chol 
alters the material properties of the bilayer acting against membrane deformation [119]. 
However, deformation is required for generating the vacancy in the bilayer that allows 
MPER insertion. So, it is likely that the higher degree of phospholipid cohesion induced 
by Chol results in shallower insertion of the MPER epitope, which allows easier access 
to the antibody. In the ternary mixture, conditions for Lo-Ld fluid phase co-existence 
are produced [120]. We have recently shown that MPER peptides might be confined 
into the Ld phase in laterally segregated systems [107]. In this case, the local increase of 
the surface concentration of exposed peptide-epitope is likely to result in more efficient 
mAb binding by enhancing avidity. 
In summary, the phenomenon of membrane-inserted epitope binding by anti-MPER 
antibodies constitutes a new paradigm of molecular recognition evolving in the 
particular milieu provided by the MI [111, 114, 115]. This bilayer region consists of a 
complex mixture of water and chemically heterogeneous phospholipid groups (polar 
head groups, glyceryl, phosphoryl, carbonyl and methylene groups) in which significant 
changes in polarity occur at short range [121]. Peptide sequence length, hydrophobicity 
distribution, membrane material properties and lipid composition are all parameters 
predicted to condition antibody recognition-blocking at the MI by modulating the 
conformation, aggregation state and bilayer topology adopted by the membrane-inserted 
MPER epitope. We surmise that upcoming effective MPER-directed immunogens will 
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be built on the optimization of those parameters. 
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Figure Legends: 
 
Figure1: Membrane-transferring regions (MTRs) of gp41 ectodomain. A) Diagram 
showing the potential to transfer from water into membrane interfaces of the sequences 
located at both ends of the gp41 ectodomain helical hairpin (for clarity, only one 
monomer of the trimeric bundle is shown). The average hydropathy plots represent 
mean values for a window of 11 amino acids, calculated according to the Wimley-White 
hydrophobicity-at-interface scale [22]. Designated regions include: FP, fusion peptide; 
NHR and CHR, amino- and carboxy-terminal helical regions, respectively; MPER, 
membrane-proximal external region; TMD, transmembrane domain. B) Model for MTR 
activity during gp41-induced membrane fusion. Gp120 subunit, which is likely to 
shelter most of the ectodomain surface, has been omitted for the sake of clarity. I) In the 
gp41 native structure MTRs fold as part of the globular ectodomain. Positions as drawn 
in the model are not based on experimental evidence, since the native ectodomain’s 
structure has not been solved with atomic resolution, and the actual organization of the 
MTRs within remains unknown. II) Pre-hairpin intermediate. Upon activation of the 
fusion cascade, MTRs are set free for insertion into the cell and viral membranes. 
Insertion restricted to one leaflet of the lipid bilayer is proposed to generate curved 
lipidic structures that prime the membrane for fusion. Even though the model suggests 
that the complete MTR-s submerge inside the membrane, insertion may involve only 
part of these regions. III) Formation of the hairpin. Membrane fusion evolves coupled to 
the completion of the 6-HB. It is assumed, but not experimentally proven, that MTRs 
and TMD-s may form membrane-bound complexes.  
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Figure 2: Isolation of fusion inhibitors based on their capacity for interfering with 
FP pore-forming activity. A) Mechanistic model for pore formation in vesicles by 
membrane active MTR peptides [72]. The model assumes that: (1) the peptides bind and 
become incorporated into the bilayer of the vesicles almost instantaneously; (2) coupled 
to partitioning the peptides adopt a defined secondary structure (an "#helix in this 
example); (3) peptide aggregation and translocation occurs within membranes; and (4) 
when an aggregate has reached a critical size, a channel or pore can be created within 
the membrane, and leakage of encapsulated molecules can occur. B) Screening of all D-
amino acid Ac-xxo3xxx-NH2 hexapeptide sub-library for inhibition of FP pore-forming 
activity. The panel represents a set of 19 hexapeptide mixtures having a defined residue 
at position 3 (X axis). The bars represent percentages of leakage increase (i.e., negative 
increase reflects inhibition). Means of four independent measurements are plotted. C) 
Effects exerted by the SCL-derived inhibitory all D-amino acid hexapeptides Ac-
gqidev-NH2 (82-2) and Ac-gqidqv-NH2 (82-5) on FP-induced POPG LUV 
permeabilization. In these assays the FP concentration was 4 µM and the hexapeptides 
were added at the FP-to-hexapeptide mole ratio of 1:40 (addition time indicated by the 
arrow). The dotted line corresponds to the fluorescence intensity increase that follows 
NBD-labeled FP insertion into the membrane. The inset further shows that the NBD 
signal had leveled off by the time the inhibitors were added. D) Dose dependency of 
FP-induced leakage inhibition by 82-2 and 82-5 (circles and squares, respectively). D-
hexapetides were either pre-incubated in DMSO with FP (dotted lines and filled 
symbols) or added to the ongoing leakage process as in the previous panel (continuous 
lines and hollow symbols). E) Effect of 82-2 and 82-5 on syncytium formation induced 
by expressed gp120/41. Top: Co-incubation of the effector and target cells at 37 °C in 
the absence of peptides resulted in extensive fusion, as evidenced by the formation of 
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syncytia (CTL panel).  When hexapeptides were present in the external solution, they 
inhibited fusion as evidenced by the large decrease in multinucleated cells in the culture 
(+82-2 panel). Bottom: Quantitation of cell-cell fusion inhibition by 82-2 (hollow 
symbols and continuous line) and 82-5 (filled symbols and dashed line). Means of two 
independent measurements are displayed. Lines correspond to best fits to hyperbolic 
functions. 
 
Figure 3: Sequence context effect on 4E10 antibody recognition-blocking of MPER 
epitope immersed in membranes. A) Comparison of NMR structures of 
665KWASLWNWFNITNWLWYIK683 and 662ELDKWASLWNWFNITNWLWYIK683 
peptides in DPC micelles (structures, derived from 1JAV [43] and 2PV6 [93] PDB 
entries, respectively, were rendered with the Swiss-PDB-viewer program). Helices are 
oriented with side chains facing the membrane HC region projecting downwards. 4E10 
epitope spans the dark gray stretch. B) CD spectra of PreTM 
(664DKWASLWNWFNITNWLWYIK683, left panel) and AISpreTM 
(656NEQELLELDKWASLWNWFNITNWLWYIK683, right panel) in DPC (5 mM) 
micelles (dotted) and POPC:Chol vesicles (continuous trace). Lipid-alone signal was 
subtracted from these samples. C) mAb4E10 inhibition of ANTS leakage induced by 
PreTM and AISpreTM (left and right panels, respectively). The antibody was added to 
vesicles 20 seconds after the peptide [92, 105]. Inhibition percentages of ongoing 
leakage were plotted as a function of mAb4E10 concentration. The dotted lines 
correspond to best fits to hyperbolic functions. D) 4E10 mAb association with 
POPC:Chol large unilamellar vesicles containing PreTM (left panel) or AISpreTM 
(right panel) as determined by flow cytometry [92]. To match conditions in the previous 
panel, vesicles were pre-incubated for 20 seconds with peptide at a 1:100 peptide-to-
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lipid molar ratio, and subsequently incubated for 10 minutes with 0 (dot line), 10 (slash 
line), 25 (slash dot line) or 40 (continuous line) µg/ml of mAb4E10. 
 
 
Figure 4: Lipid composition effect on 4E10 antibody recognition-blocking of 
MPER epitope immersed in membranes. A) Accessibility of membrane-bound 
peptides to proteolytic degradation. Vesicles (100 µM lipid) containing Rhodamine-
labelled PreTM peptide (1:500 peptide to lipid mole ratio) were treated with Proteinase 
K (60 #g/ml, addition time indicated by the arrow). The kinetic traces follow the 
rhodamine fluorescence increase as a function of time. B) mAb4E10 recognition-
extraction of PreTM sequence inserted into lipid monolayers. The panels show the 
decrease in lateral surface pressure of peptide-containing monolayers induced upon 
injection of 4E10 antibody into the subphases (25 µg, at the time indicated by the 
arrow). Conditions otherwise as those described in reference [105]. C) 4E10 mAb 
association with PreTM-containing vesicles as determined by flow cytometry [92]. 
Vesicles (0.25 mM lipid) pre-incubated for 5 minutes with peptide at a 1:100 peptide-
to-lipid molar ratio, were subsequently incubated for 10 minutes with 0 (dot line), 5 
(slash line) or 20 (continuous line) µg/ml of mAb4E10. 
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